U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Emergency Preparedness and Response
  3. Public Health Preparedness and Response
  4. Innovative Technologies
  5. Innovative Technologies Regulatory Science Research
  1. Innovative Technologies

Innovative Technologies Regulatory Science Research

ORES funds intramural and extramural regulatory science research to support adoption of cross-cutting innovative and emerging technologies.

Image
People collaborating near a white board with multiple charts

On this page: Research areas | Current projects | Completed projects | Resources for You

To develop the tools, standards, and approaches necessary to support the adoption of innovative and emerging technologies, the Office of Regulatory and Emerging Science (ORES) provides funding in high-priority regulatory science research areas for internal FDA scientists as well as for external research groups that align with U.S. Government priorities.

Our goal is to strengthen the FDA’s ability to respond to public health emergencies, increase manufacturing flexibility and improve supply chain resilience to prevent and address product shortages, and ensure the safety, efficacy, and quality of FDA-regulated products.  

Extramural Funding

ORES funds extramural research for emerging and innovative technology-related regulatory science with several mechanisms, primarily using the FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. Full application information and instructions for the current BAA are available at SAM.gov

Intramural Funding

Funding for intramural emerging technology regulatory science is primarily provided through competitive awards under the Medical Countermeasures Regulatory Science Challenge Grants Program

Priority Research Interest Areas

  • Innovative and emerging technologies such as advanced manufacturing- including continuous, additive, and smart manufacturing 
  • Supply chain resilience including technologies to prevent or mitigate medical product shortages and/or speed time to market 
  • Alternative methods for regulatory use such engineered tissues (e.g., using scaffolds and cells to form biologically active tissues), artificial Intelligence (e.g., using computer (aka in silico) approaches), complex In Vitro models (e.g., alternative organisms such as Zebrafish and C. elegans), and novel in vitro systems (e.g., microphysiological systems (MPS), including organs-on-chips)

ORES Collaborations

In addition to funding high-impact projects, the ORES Advanced Manufacturing Program is active in external and interagency collaboration activities. These activities allow the FDA to contribute to ongoing work outside of the Agency, including standards development and industry roadmaps, as well as learn from industry stakeholders about the state-of-the-art science. 

Project  Partner(s)
VHA Digital Stockpile National Response Network MOU Veterans Health Administration (VHA) 
Digital Stockpile and National Response Network Roundtable  VHA, Radiological Society of North America (RSNA), America Makes 
America Makes and ANSI Additive Manufacturing Standardization Collaborative (AMSC) Roadmap America Makes, American National Standards Institute (ANSI)

Current Extramural Projects

Project  Awardee
Initiative to benchmark and profile monoclonal antibody and large biomolecule stability
 
National Institute of Standards and Technology (NIST)

Applying Additive Manufacturing for Continuous Production of Extracellular Vesicle Products

CERSI- University of Maryland
Noninvasive PAT for Manufacturing Automation
 
University of Maryland
An X-ray based inline probe for real-time process monitoring of the crystallization of active pharmaceutical ingredients (API) in manufacturing drug products University of Maryland

Completed Extramural Projects

Project  Awardee
FDA Advanced Manufacturing Evaluation
 
Booz Allen Hamilton
Analysis of the Advantages of and Barriers to Adoption of Smart Manufacturing for Medical Products
 
MxD (The Digital Manufacturing and Cybersecurity Institute) and IAAE
Assessing the Role of Additive Manufacturing in Support of the U.S. COVID-19 Response
 
America Makes, National Center for Defense Manufacturing & Machining 
Landscape Analysis of Adoption of Advanced Manufacturing in Non-Medical Industries
 
Booz Allen Hamilton

Completed Intramural Projects

Project  Awardee Center
Improving Influenza Vaccine Reagent Production Jerry Weir CBER

Testing and modelling decontamination, microbial exposure, and performance with a Repertoire of N95 respirators and surgical masks

Enusha Karunasena CDRH

Resources For You

Subscribe

Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases, and advanced manufacturing.

Back to Top